Robert O'connor

List of Publications by Year
in descending order

35 papers	1,172 citations	361045 20 h-index	377514 34 g-index
37 all docs	37 docs citations	37 times ranked	2397 citing authors

#	Article	IF	Citations
1	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer, 2011, 10, 126.	7.9	170
2	The pharmacology of cancer resistance. Anticancer Research, 2007, 27, 1267-72.	0.5	93
3	Stable Aqueous Dispersions of Glycopeptide–Grafted Selectably Functionalized Magnetic Nanoparticles. Angewandte Chemie - International Edition, 2013, 52, 3164-3167.	7.2	79
4	The Pharmacology, Metabolism, and Chemistry of Clofazimine. Drug Metabolism Reviews, 1995, 27, 591-614.	1.5	65
5	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemotherapy and Pharmacology, 2013, 71, 1357-1368.	1.1	62
6	Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. Scientific Reports, 2017, 7, 44541.	1.6	61
7	Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 805-817.	1.5	51
8	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	1.1	47
9	Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 618-627.	1.1	47
10	Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3982-3990.	1.2	38
11	Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. International Journal of Cancer, 2004, 111, 484-493.	2.3	35
12	A novel panel of protein biomarkers for predicting response to thalidomide–based therapy in newly diagnosed multiple myeloma patients. Proteomics, 2011, 11, 1391-1402.	1.3	33
13	Rapid and sensitive liquid chromatography–tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples. Talanta, 2007, 72, 145-154.	2.9	32
14	Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. PLoS ONE, 2015, 10, e0140273.	1.1	29
15	CE–LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration. Journal of Separation Science, 2008, 31, 1828-1833.	1.3	27
16	Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Research and Treatment, 2008, 110, 521-530.	1.1	25
17	Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved. Toxicology in Vitro, 2008, 22, 582-588.	1.1	23
18	Simultaneous determination of anthracyclines and taxanes in human serum using online sample extraction coupled to high performance liquid chromatography with UV detection. Journal of Separation Science, 2010, 33, 1571-1579.	1.3	23

#	Article	IF	Citations
19	Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Research, 2004, 24, 457-64.	0.5	23
20	Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 785-791.	1.4	22
21	Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. Molecular Cancer, 2012, 11, 41.	7.9	22
22	Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. DARU, Journal of Pharmaceutical Sciences, 2015, 23, 40.	0.9	21
23	A gene expression profile indicative of early stage HER2 targeted therapy response. Molecular Cancer, 2013, 12, 69.	7.9	20
24	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Cancers, 2019, 11, 548.	1.7	19
25	Modulation of P-gp expression by lapatinib. Investigational New Drugs, 2011, 29, 1284-1293.	1.2	16
26	Recent developments in drug resistance and apoptosis research. Critical Reviews in Oncology/Hematology, 1998, 28, 181-205.	2.0	15
27	Determination of serum and tissue levels of phenazines including clofazimine. Biomedical Applications, 1996, 681, 307-315.	1.7	14
28	The use of <scp>LC</scp>â€<scp>MS</scp> to identify differentially expressed proteins in docetaxelâ€resistant prostate cancer cell lines. Proteomics, 2012, 12, 2115-2126.	1.3	13
29	Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. International Journal of Molecular Sciences, 2020, 21, 962.	1.8	12
30	Development, validation and application of a sensitive LCâ€"MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 16-26.	1.2	11
31	Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells. Data in Brief, 2016, 6, 1023-1027.	0.5	9
32	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.. Blood, 2009, 114, 1729-1729.	0.6	7
33	Challenges in molecular analysis for individualized cancer therapy. Drug Discovery Today, 2003, 8, 531.	3.2	2
34	Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models. PLoS ONE, 2017, 12, e0177058.	1.1	2
35	Determination Of The Proteomic Response To Lapatinib Treatment Using A Comprehensive And Reproducible Ion-current-based Proteomics Strategy. Journal of Proteomics and Genomics Research, 2013, 1, 27-42.	0.7	2